Hong Daewha, Flood Pamela, Diaz Geraldine
Department of Anesthesiology, Columbia University Medical Center, 630 West 168th St. New York City, NY 10032, USA.
Anesth Analg. 2008 Oct;107(4):1384-9. doi: 10.1213/ane.0b013e3181823efb.
Despite "clinical lore" among health care providers that treatment with hydromorphone results in improved pain control and fewer adverse side effects, morphine continues to be the first-line medication for postoperative patient-controlled analgesia (PCA). In this study, we compared the efficacy and side-effect profiles of morphine and hydromorphone at concentrations producing equivalent drug effect measured by pain score and miosis.
We conducted a prospective, randomized, double-blind trial of 50 general and gynecological surgery patients. Subjects were randomly assigned to receive either morphine (1 mg/mL) or hydromorphone (0.2 mg/mL) via PCA after surgery and were followed for a period of 8 h. The primary outcome was nausea. Secondary outcome variables were pruritus, vomiting, sedation, pain report, pupillary miosis, and patient satisfaction.
The side effect profile was not different between drugs. The incidence of nausea did not differ between morphine and hydromorphone-treated patients (1 h: 44% vs 52%, 8 h: 68% vs 64%), vomiting (1 h: 4% vs 0%, 8 h: 0% vs 4%), or pruritus (1 h: 4% vs 16%, 8 h: 40% vs 40%). There was no difference in the amount of medication required to treat side effects or patient satisfaction. The average ratio of morphine to hydromorphone use was about 7:1. The patients used 10.9+/-6.0 mg morphine versus 1.57+/-1.0 mg hydromorphone after 1 h and 29.0+/-18.0 mg morphine versus 3.9+/-2.5 mg hydromorphone after 8 h. There was no difference between the morphine and hydromorphone groups with respect to postoperative pain scores with movement at 1 h (7.9+/-2.3 vs 7.1+/-2.4) or 8 h (5.7+/-2.8 vs 5.9+/-2.7). There was also no difference in pain at rest or miosis between groups.
We found no systematic difference between morphine and hydromorphone in opioid-related side effects. Neither was there any difference in efficacy of pain control or patient satisfaction when patients self-titrated to equal drug effect as measured by equianalgesia and pupillary miosis. The choice between morphine and hydromorphone for use in PCA should be guided by patient history, as there may be idiosyncratic reactions to either drug.
尽管医疗服务提供者中有“临床经验”表明,使用氢吗啡酮进行治疗可改善疼痛控制且减少不良副作用,但吗啡仍是术后患者自控镇痛(PCA)的一线用药。在本研究中,我们比较了吗啡和氢吗啡酮在通过疼痛评分和瞳孔缩小测量产生等效药物效果的浓度下的疗效和副作用情况。
我们对50例普通外科和妇科手术患者进行了一项前瞻性、随机、双盲试验。受试者在术后通过PCA随机分配接受吗啡(1mg/mL)或氢吗啡酮(0.2mg/mL)治疗,并随访8小时。主要结局是恶心。次要结局变量包括瘙痒、呕吐、镇静、疼痛报告、瞳孔缩小和患者满意度。
两种药物的副作用情况无差异。吗啡组和氢吗啡酮组患者的恶心发生率无差异(1小时:44%对52%,8小时:68%对64%)、呕吐发生率无差异(1小时:4%对0%,8小时:0%对4%)或瘙痒发生率无差异(1小时:4%对16%,8小时:40%对40%)。治疗副作用所需的药物量或患者满意度也无差异。吗啡与氢吗啡酮的使用平均比例约为7:1。患者在1小时后使用10.9±6.0mg吗啡,而使用1.57±1.0mg氢吗啡酮;8小时后使用29.0±18.0mg吗啡,而使用3.9±2.5mg氢吗啡酮。吗啡组和氢吗啡酮组在术后1小时(7.9±2.3对7.1±2.4)或8小时(5.7±2.8对5.9±2.7)活动时的疼痛评分无差异。两组在静息时的疼痛或瞳孔缩小方面也无差异。
我们发现吗啡和氢吗啡酮在阿片类药物相关副作用方面无系统性差异。当患者根据等效镇痛和瞳孔缩小自我滴定至等效药物效果时,在疼痛控制疗效或患者满意度方面也无差异。在PCA中使用吗啡还是氢吗啡酮应根据患者病史来决定,因为可能对其中任何一种药物存在特异反应。